Patents by Inventor George Doherty

George Doherty has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240285611
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: August 15, 2023
    Publication date: August 29, 2024
    Applicant: ABBVIE INC.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Publication number: 20240228509
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 3, 2023
    Publication date: July 11, 2024
    Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Andreas Kling, Frauke Pohlki, Jessee Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Michael Michaelides
  • Publication number: 20240199745
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: July 10, 2023
    Publication date: June 20, 2024
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • Publication number: 20240058450
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: May 31, 2022
    Publication date: February 22, 2024
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Publication number: 20230399340
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: October 12, 2022
    Publication date: December 14, 2023
    Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Andreas Kling, Frauke Pohlki, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Michael Michaelides
  • Patent number: 11786519
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Grant
    Filed: September 16, 2020
    Date of Patent: October 17, 2023
    Assignee: ABBVIE INC.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Publication number: 20220259226
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: April 22, 2022
    Publication date: August 18, 2022
    Inventors: Wilfried Braje, George Doherty, Katja Jantos, Cheng Ji, Andrew Judd, Aaron Kunzer, Anthony Mastracchio, Xiaohong Song, Andrew Souers, Gerard Sullivan, Zhi-Fu Tao, Chunqiu Lai, Jesse Teske, Michael Wendt, Patrick Brady, Xilu Wang, Thomas Penning, Yujia Dai, Jane Gong, Roberto Risi, Yiyun Yu, Guidong Zhu
  • Publication number: 20210346369
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 1, 2020
    Publication date: November 11, 2021
    Applicant: AbbVie Inc.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Publication number: 20210292339
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: October 23, 2020
    Publication date: September 23, 2021
    Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Yujia DAI, Jane GONG, Roberto RISI, Yiyun YU, Guidong ZHU
  • Publication number: 20210228565
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: September 16, 2020
    Publication date: July 29, 2021
    Applicant: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Publication number: 20200345717
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: December 18, 2019
    Publication date: November 5, 2020
    Applicant: AbbVie Inc.
    Inventors: Le WANG, George DOHERTY, Xilu WANG, Zhi-Fu TAO, Milan BRUNCKO, Aaron R. KUNZER, Michael D. WENDT, Xiaohong SONG, Robin FREY, Todd M. HANSEN, Gerard M. SULLIVAN, Andrew JUDD, Andrew SOUERS
  • Publication number: 20200253954
    Abstract: Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-xL proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-xL protein.
    Type: Application
    Filed: September 20, 2019
    Publication date: August 13, 2020
    Applicant: AbbVie Inc.
    Inventors: Le Wang, George Doherty, Xilu Wang, Zhi-Fu Tao, Milan Bruncko, Aaron R. Kunzer, Michael D. Wendt, Xiaohong Song, Robin Frey, Todd M. Hansen, Gerard M. Sullivan, Andrew Judd, Andrew Souers
  • Publication number: 20200255451
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents for the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: August 13, 2020
    Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Andreas KLING, Frauke POHLKI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Yujia DAI, Jane GONG, Roberto RISI, Yiyun YU, Guidong ZHU, Dominique POTIN, Fabrice Guillier
  • Publication number: 20200246323
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: May 15, 2019
    Publication date: August 6, 2020
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Erwin R. Boghaert, Milan Bruncko, George Doherty, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-fu Tao, Xilu Wang, Dennle S. Welch
  • Publication number: 20200246460
    Abstract: The present disclosure concerns Bcl-xL inhibitors having low cell permeability, antibody drug conjugates (ADCs) comprising the inhibitors, synthons useful for synthesizing the ADCs, compositions comprising the inhibitors or ADCs, and various methods of using the inhibitors and ADCs.
    Type: Application
    Filed: September 6, 2019
    Publication date: August 6, 2020
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Violeta L. Marin, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Publication number: 20200239553
    Abstract: Small molecule Bcl-xL inhibitors and Antibody Drug Conjugates (ADCs) comprising small molecule Bcl-xL inhibitors are disclosed herein. The Bcl-xL inhibitors and ADCs of the disclosure are useful for, among other things, inhibiting anti-apoptotic Bcl-xL proteins as a therapeutic approach towards the treatment of diseases that involve a dysregulated apoptosis pathway.
    Type: Application
    Filed: November 6, 2019
    Publication date: July 30, 2020
    Applicant: AbbVie Inc.
    Inventors: Scott L. Ackler, Nathan B. Bennett, Erwin R. Boghaert, Steve C. Cullen, George Doherty, Robin R. Frey, Anthony R. Haight, Andrew S. Judd, Aaron R. Kunzer, Xiaoqiang Shen, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao, Xilu Wang, Dennie S. Welch, Michael D. Wendt
  • Publication number: 20200239494
    Abstract: The present disclosure provides for compounds of Formula (I) wherein A2, A3, A4, A6, A7, A8, A15, RA, R5, R9, R10A, R10B, R11, R12, R13, R14, R16, W, X, and Y have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including cancer. Also provided are pharmaceutical compositions comprising compounds of Formula (I).
    Type: Application
    Filed: August 15, 2018
    Publication date: July 30, 2020
    Inventors: Wilfried BRAJE, George DOHERTY, Katja JANTOS, Cheng JI, Andrew JUDD, Aaron KUNZER, Anthony MASTRACCHIO, Xiaohong SONG, Andrew SOUERS, Gerard SULLIVAN, Zhi-Fu TAO, Chunqiu LAI, Andreas KLING, Frauke POHLKI, Jesse TESKE, Michael WENDT, Patrick BRADY, Xilu WANG, Thomas PENNING, Michael Michaelides
  • Publication number: 20200002421
    Abstract: The invention relates to B7 homology 3 protein (B7-H3) antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: January 2, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, Debra Chao, Kamel Izeradjene, Andrew S. Judd, Andrew C. Phillips, Andrew J. Souers, Archana Thakur, George Doherty, Robin R. Frey, Xiaohong Song, Gerard M. Sullivan, Zhi-Fu Tao
  • Publication number: 20200002432
    Abstract: The invention relates to anti-CD98 antibodies and antibody drug conjugates (ADCs), including compositions and methods of using said antibodies and ADCs.
    Type: Application
    Filed: June 8, 2017
    Publication date: January 2, 2020
    Inventors: Lorenzo Benatuil, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Yingchun Li, Andrew Mccluskey, Andrew C. Phillips, Darren C. Phillips, Jane Seagal, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao
  • Publication number: 20190153107
    Abstract: The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.
    Type: Application
    Filed: June 7, 2017
    Publication date: May 23, 2019
    Applicant: AbbVie Inc.
    Inventors: Erwin R. Boghaert, Milan Bruncko, George Doherty, Robin R. Frey, Andrew S. Judd, Andrew C. Phillips, Xiaohong Song, Andrew J. Souers, Gerard M. Sullivan, Zhi-Fu Tao